If the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for NTLA-2001. Image Source: Zacks Investment Research This apart, NTLA submitted a clinical trial application to initiate a first-in-human phase I study of NTLA-3001 in December 2023. The company plans to begin patient dosing later in 2024. Some better-ranked stocks in the healthcare sector are Acrivon Therapeutics, Inc. (ACRV) and Aligos Therapeutics, Inc. (ALGS) , each carrying a Zacks Rank #2 (Buy) at ...